Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : ALNY save search
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Published: 2022-09-08 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -1.67%
H: 10.61%
C: 10.19%
positive results study
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
Published: 2021-04-21 (Crawled : 12:00) - vbivaccines.com
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: -1.09%
H: 0.38%
C: 0.04%
VBIV | $0.591 -1.99% -2.03% 110K
|
Health Technology
|
| O: 0.0%
H: 7.66%
C: 7.66%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.67%
H: 1.12%
C: 0.43%
treatment phase 2 hepatitis vbi-2601 biotech vaccine technology iot brii-835 trial
Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021
Published: 2021-11-04 (Crawled : 18:00) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: 0.06%
H: 0.26%
C: 0.19%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 3.16%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.24%
H: 7.69%
C: 7.59%
kidney
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-22 (Crawled : 00:00) - biospace.com/
XNCR | $18.35 0.77% 0.76% 480K
|
Health Technology
|
| O: -0.87%
H: 2.89%
C: 2.14%
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: -0.69%
H: 2.99%
C: 2.59%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.17%
H: 6.18%
C: 5.4%
year update financial results
Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results
Published: 2022-10-13 (Crawled : 13:00) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -1.53%
H: 5.32%
C: 5.2%
conference financial results
Alnylam Announces New Advances in ATTR Amyloidosis Program
Published: 2021-05-11 (Crawled : 12:00) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -1.69%
H: 5.46%
C: 4.71%
program
Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera
Published: 2023-08-03 (Crawled : 11:00) - globenewswire.com
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -1.35%
H: 5.58%
C: 4.38%
AGIO | $31.82 5.33% 5.06% 1.2M
|
Health Technology
|
| O: -2.4%
H: 5.98%
C: 2.81%
license treatment potential agreement
Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Published: 2021-01-07 (Crawled : 15:00) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 5.35%
H: 4.77%
C: 4.33%
positive results phase 3 topline
Opinion: Brain Health Matters; We Must Not Lose Momentum
Published: 2024-01-08 (Crawled : 07:00) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.05%
H: 4.12%
C: 3.98%
health momentum
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
Published: 2023-12-13 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.06%
H: 2.36%
C: 2.36%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.27%
H: 2.28%
C: 2.16%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.14%
H: 4.22%
C: 3.97%
day innovation pipeline platform
Dicerna to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference
Published: 2021-06-03 (Crawled : 22:00) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -0.05%
H: 1.1%
C: 1.1%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.07%
H: 2.34%
C: 1.86%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.72%
H: 4.77%
C: 3.86%
conference
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Published: 2022-06-14 (Crawled : 07:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.73%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.77%
H: 6.48%
C: 3.71%
treatment fda approval
Alnylam Announces 2022 Product and Pipeline Goals and Provides Program Updates at R&D Day
Published: 2021-11-19 (Crawled : 12:30) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -2.38%
H: 4.35%
C: 3.59%
RNAi Roundtable: Givosiran, for the Treatment of Acute Hepatic Porphyria
Published: 2021-08-04 (Crawled : 18:00) - alnylam.com
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -0.88%
H: 5.21%
C: 3.5%
treatment hepatitis
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
Published: 2021-08-09 (Crawled : 12:15) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.37%
H: 4.18%
C: 3.46%
media phase 3 cardio enroll
Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update
Published: 2021-08-09 (Crawled : 12:15) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: 1.64%
H: 0.89%
C: 0.58%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.33%
H: 3.2%
C: 0.98%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.37%
H: 4.18%
C: 3.46%
financial results results
Alnylam Issues Inaugural Corporate Responsibility Summary
Published: 2021-03-11 (Crawled : 14:19) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 2.62%
H: 3.97%
C: 3.45%
response
HELIOS-A Phase 3 Results for Vutrisiran Presented at AAN
Published: 2021-04-19 (Crawled : 19:00) - alnylam.com
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -4.11%
H: 3.92%
C: 3.25%
results phase 3 presentation
Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity
Published: 2021-07-01 (Crawled : 21:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.27%
H: 0.36%
C: 0.08%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.35%
H: 3.65%
C: 3.24%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.11%
H: 0.21%
C: 0.03%
obesity genetic
Alnylam Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 12:00) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.19%
H: 3.41%
C: 3.14%
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.